Month: January 2022

Taboola Launches “Homepage For You” Artificial Intelligence Technology, Empowering Editors to Make Homepages as Personalized and Engaging as the World’s Top Social Apps; Offering Drives More Than 30% Increase in CTRs

Written by Customer Service on January 26, 2022. Posted in Public Companies.

Leading publishers McClatchy, The Independent, Estado de Minas Among Early Users; Homepage For You Bolsters Taboola Newsroom Offering to Help Editors Compete Against Social Networks Through PersonalizationTaboola Homepage For YouHomepage For You helps editors power their homepages, their most visited and prominent section of their website, to capture attention by leveraging Taboola’s advanced A.I. and proven recommendation platform–the same technology used by over 9,000 global publishers.NEW YORK, Jan. 26, 2022 (GLOBE NEWSWIRE) — Taboola, a global leader in powering recommendations for the open web, helping people discover things they may like, today announced a new milestone for its publisher platform that adds A.I. to power editorial recommendations on publisher homepages, an offering already being used...

BrainsWay Announces Addition of Markus Heilig, M.D., Ph.D., to Scientific Advisory Board

Written by Customer Service on January 26, 2022. Posted in Public Companies.

World-Renowned Specialist in Addiction and Anxiety Treatment Joins Premier Group of Researchers and Clinicians Advising Company BURLINGTON, Mass. and JERUSALEM, Jan. 26, 2022 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced the addition of Professor Markus Heilig, M.D., Ph.D., to BrainsWay’s scientific advisory board. “It is my distinct pleasure to welcome Professor Heilig to our scientific advisory board,” said Christopher von Jako, Ph.D., President and CEO of BrainsWay. “His extensive body of research has helped lay the foundation upon which we continue to build clinical advancements, including his recent results treating alcohol dependent patients with Deep TMS™. As a luminary in the field, Professor...

Bionano Genomics Announces Publication of the First Study to Combine OGM and NGS to Evaluate Myeloid Cancers

Written by Customer Service on January 26, 2022. Posted in Public Companies.

Whole genome analysis by OGM together with analysis using a 523-gene NGS panel can perform better and cost less than analysis with karyotyping, FISH, and a 54-gene NGS panel First study to publish results using NxClinical software for simultaneous visualization and interpretation of sequence and copy number variants from NGS and OGM dataSAN DIEGO, Jan. 26, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data today announced the publication of a study that evaluated the performance and clinical utility of combining OGM and a 523-gene next-generation sequencing (NGS) panel for comprehensive evaluation of myeloid tumors and compared...

Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)

Written by Customer Service on January 26, 2022. Posted in Public Companies.

Administration of single ascending doses up to 480 mg in healthy volunteers nearly complete First chronic hepatitis B patient dosed in initial cohort, each of which will be administered 7 subcutaneous doses over 29 days SOUTH SAN FRANCISCO, Calif., Jan. 26, 2022 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the first chronic hepatitis B (CHB) patient has been dosed in the multiple ascending dose (MAD) portion of Study ALG-020572-401 (NCT05001022) which is evaluating antisense oligonucleotide (ASO) ALG-020572. “We are pleased to have initiated the MAD phase of this study in CHB patients,” said Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos....

ST. JAMES GOLD CORP. (TSX-V: LORD) ADDS SENIOR MINING EXECUTIVE TERENCE F. COUGHLAN, P.GEO, TO ITS BOARD OF ADVISORS

Written by Customer Service on January 26, 2022. Posted in Public Companies.

St. James Gold Corp.Terence F. Coughlan, P.Geo, has joined the company’s Board of Advisors.Vancouver, British Columbia, Jan. 26, 2022 (GLOBE NEWSWIRE) — St. James Gold Corp. (the “Company”) (TSXV: LORD) (OTCQB: LRDJF) (FSE: BVU3) is pleased to announce that Terence F. Coughlan, P.Geo, has joined the company’s Board of Advisors. Mr. Coughlan’s appointment follows the Company’s recent appointment of Sean Tufford as director of business development. Together, they bring a track record of success and significant mining experience to the Company at a time of transformative development in Newfoundland and the Yukon. Actively involved in the mineral resource industry since 1984, Mr. Coughlan brings with him a nearly 40-year record of success in mineral exploration, operations and corporate development. The founding Chief...

O2Micro Reports Fourth Quarter 2021 Financial Results

Written by Customer Service on January 26, 2022. Posted in Public Companies.

GEORGE TOWN, Grand Cayman, Jan. 26, 2022 (GLOBE NEWSWIRE) — Operational Highlights:2021 Q4 revenue was $24.4 million.Revenue increased 4.9% compared to the same quarter in 2020.GAAP net income was $0.09 per fully diluted ADS, down from $0.14 per fully diluted ADS, for the same quarter a year ago.O2Micro expects the first quarter 2022 revenue to be in the range of $20.0 million to $22.0 million. O2Micro® International Limited (NASDAQ: OIIM)(O2Micro), a global leader in the design, development and marketing of high-performance integrated circuits and solutions, reported its financial results today for the fourth quarter ending December 31, 2021. Financial Highlights for the Fourth Quarter ending December 31, 2021: O2Micro reported the fourth quarter 2021 revenue of $24.4 million within the revised guidance announced on...

Yuengling’s Ice Cream Signs Letter of Intent for the Acquisition of an Ice Cream Production Facility

Written by Customer Service on January 26, 2022. Posted in Mergers And Acquisitions.

ATLANTA, GA, Jan. 26, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Yuengling’s Ice Cream Corporation (“Yuengling’s”) (OTC PINK: ARSN) is pleased to announce that it has signed a Letter of Intent (LOI) for the acquisition of an ice cream production facility. The counterparty to the sale has requested that its name remain confidential for the moment. Both parties expect the transaction to close by the end of March 2022. Additional details of the deal will be released in the next few weeks. “While specific details are not yet being made available, we are very excited about the acquisition as it will not only allow the company to produce Yuengling’s ice cream but also ice cream for other brands,” commented Rob Bohorad, Yuengling’s President and CEO. “In addition, with ice cream production availability limited across the country, this...

Fairfax India to Acquire 70% of Jaynix Engineering Private Limited

Written by Customer Service on January 26, 2022. Posted in Mergers And Acquisitions.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES (Note: All dollar amounts in this news release are expressed in U.S. dollars, except as otherwise noted). TORONTO, Jan. 26, 2022 (GLOBE NEWSWIRE) — Fairfax India Holdings Corporation (“Fairfax India” or the “Company”) (TSX: FIH.U) announces that, through its wholly-owned subsidiary, it has entered into an agreement to invest INR 2.45 billion (approximately $33 million at current exchange rates) for a 70% equity interest in Jaynix Engineering Private Limited (“Jaynix”). The transaction is subject to customary closing conditions and is expected to close in the first quarter of 2022. Jaynix is a manufacturing company engaged in the production of non-ferrous electrical connectors and electrical assemblies and is a critical Tier 1 supplier to major...

PolyPid to Report Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights on February 9, 2022

Written by Customer Service on January 26, 2022. Posted in Public Companies.

PETACH TIKVA, Israel, Jan. 26, 2022 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its fourth quarter and full year 2021 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, February 9, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information:Date: Wednesday, February 9, 2022Time: 8:30 AM Eastern TimeUnited States: +1 877-870-9135Israel: +972 1809 213-985International: +44 (0) 2071 928338Conference...

Stock Yards Bancorp Reports Record 2021 Earnings and Strong Fourth Quarter Earnings of $24.6 Million or $0.92 per Diluted Share

Written by Customer Service on January 26, 2022. Posted in Public Companies.

Highlighted by Solid Organic Balance Sheet Growth and Record Levels of Non-Interest Income LOUISVILLE, Ky., Jan. 26, 2022 (GLOBE NEWSWIRE) — Stock Yards Bancorp, Inc. (NASDAQ: SYBT), parent company of Stock Yards Bank & Trust Company, with offices in Louisville, Central and Eastern Kentucky, as well as the Indianapolis, Indiana and Cincinnati, Ohio metropolitan markets, today reported earnings for the fourth quarter ended December 31, 2021. Net income for the fourth quarter was $24.6 million, or $0.92 per diluted share, compared with net income of $17.7 million, or $0.78 per diluted share, for the fourth quarter of 2020. Net income for the twelve months ended December 31, 2021 ended at a record $74.6 million, or $2.97 per diluted share, compared to $58.9 million, or $2.59 per diluted share, in 2020. Strong organic balance...

Month: January 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals